ERBB2 and triple-negative breast carcinoma: Despite the lower cytotoxic response, due to a lack of HER2 expression, this result proposes that cats with HER2-negative tumors may benefit from the use of trastuzumab, as suggested for human triple-negative breast cancer that expresses an activated form of HER2 (HER2Y877) [108].